<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097990</url>
  </required_header>
  <id_info>
    <org_study_id>6390-19-SMC</org_study_id>
    <nct_id>NCT04097990</nct_id>
  </id_info>
  <brief_title>Characterization of Fatty Acid Composition of Triglycerides in Patients With Hypertriglyceridemia-induced Acute Pancreatitis</brief_title>
  <official_title>Characterization of Fatty Acid Composition of Triglycerides in Patients With Hypertriglyceridemia-induced Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ) Finding a unique pattern in the triglyceride composition of patients with
      hypertriglyceridemia that increases the chances of getting pancreatitis and which can serve
      as a laboratory predictive tool for patients and define them as a at-risk population.

      2) Finding the typical fatty acid composition in triglycerides for patients at high risk of
      pancreatic acute inflammation that can be used to develop unique drugs for pancreatic acute
      inflammation caused by high levels of triglycerides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at the Sheba Medical Center Lipid Institute, number of
      participants: 10 healthy participants, 10 participants with hypertriglyceridemia without
      prior pancreatitis and 10 participants with hypertriglyceridemia and at least one case of
      severe pancreatitis in the last 5 years.

      A total of 30 participants Participants who are found suitable during their visit to the
      Lipid Institute Clinic or during their hospitalization at Sheba Medical Center will receive
      an explanation of the study, will be asked to sign a consent form. And check the fatty acid
      levels. Healthy volunteers who meet the inclusion conditions will also be asked to sign a
      consent form and their blood will be taken and kept frozen for further study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>10 healthy participants, 10 participants with hypertriglyceridemia without prior pancreatitis and 10 participants with hypertriglyceridemia and at least one case of severe pancreatitis in the last 5 years.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Finding a unique pattern in the triglyceride composition</measure>
    <time_frame>one year</time_frame>
    <description>Fatty acids will be analyzed in a gas-chromatographer and their concentration in plasma will be measured by comparison to a known-consentration standard fatty acid solution. Concentration will be presented as mg/dL (miligrams per deciliter) or as a fold change concentration relative to the concentration in plasma of control subjects.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>healthy participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertriglyceridemia without prior pancreatit</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertriglyceridemia and at least one case of</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels</description>
    <arm_group_label>healthy participants</arm_group_label>
    <arm_group_label>hypertriglyceridemia and at least one case of</arm_group_label>
    <arm_group_label>hypertriglyceridemia without prior pancreatit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Healthy participants - triglyceride levels&lt; 150 mg / dl over the past 5 years, with
             no diabetes or cardiovascular disease in the background.

             2) Participants with triglyceride levels 1000-5000 mg / dl without acute pancreatitis
             cases in the past.

             3) Participants with triglyceride levels 1000-5000 mg / dL and at least one case of
             acute pancreatitis in the last 5 years.

        Exclusion Criteria:

          1. A past pancreatitis event that occurred with measurement of triglyceride levels
             greater than 5000 mg / dL.

          2. Acute pancreatitis events in the past that occurred for a cause other than
             hypertriglyceridemia -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>tamar luvish, BSN</last_name>
    <phone>972-35303492</phone>
    <email>tamar.luvish@sheba.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lipid center</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>tamar luvish, BSN</last_name>
      <phone>972-35303492</phone>
      <email>tamar.luvish@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Rom Keshet</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Absolute medical confidentiality will be kept on all participants' details. All details will be kept locked while the tests containing the participants' blood or the biological materials produced from it will be marked in serial numbers only.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

